.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Combination Strategies with BCL2-Targeted Therapy

EP. 1: Deciding a Frontline Treatment for Newly Diagnosed AML

June 24th 2019

EP. 2: Frontline Venetoclax Combination Therapy for AML

June 24th 2019

EP. 3: Targeted Approaches to Treating AML

June 24th 2019

EP. 4: Role of FLT3 Inhibitors for Treating Relapsed AML

June 24th 2019

EP. 5: The Future of BCL2i Combination Therapies

June 24th 2019

EP. 6: Recent Breakthroughs in the Treatment of Refractory CLL

June 24th 2019

EP. 7: The MURANO Phase III Trial

June 24th 2019

EP. 8: The Future of Targeted Management for CLL

June 24th 2019

EP. 9: Notable CLL Abstracts and Trials from ASCO 2019

June 24th 2019